Skip to main content
Peptide compounds discussed on this site are for educational and research purposes. Always consult a qualified specialist before use.
CONDITION

Fat Loss & Metabolism

Metabolic dysfunction and excess adipose tissue, particularly visceral fat deposited around internal organs, represent significant health risks beyond cosmetic concerns. Visceral adipose tissue is metabolically active, secreting inflammatory cytokines, disrupting insulin signaling, and contributing to cardiovascular disease risk.

[ OVERVIEW ]

Understanding Fat Loss & Metabolism

Traditional approaches to fat loss focus on caloric restriction and exercise, which remain foundational but are often insufficient for addressing stubborn metabolic dysfunction, particularly in cases of hormonal decline, insulin resistance, or age-related metabolic slowdown. Peptide research has identified compounds that target fat metabolism through growth-hormone-related pathways, offering mechanisms that complement dietary and exercise interventions. These compounds work by enhancing lipolysis (fat breakdown), inhibiting lipogenesis (fat storage), improving insulin sensitivity, and optimizing mitochondrial energy production, the fundamental metabolic processes that determine body composition. The three peptides studied for fat loss and metabolism, AOD-9604, Tesamorelin, and MOTS-c, represent three distinct approaches to metabolic optimization. AOD-9604 provides isolated GH-fragment lipolysis without hormonal side effects. Tesamorelin stimulates full pulsatile GH release for comprehensive metabolic benefits including FDA-proven visceral fat reduction. MOTS-c activates AMPK for exercise-mimetic metabolic enhancement. Understanding these mechanisms allows specialists to select the approach best suited to each individual's metabolic profile and goals.

Medical Disclaimer

The information presented here is for educational purposes. Consult a qualified specialist before using any peptide compound.

Recommended 3 peptides
Protocol Phases 3
References Peer-reviewed
Evidence Graded Yes
Free consultation
[ COMPOUNDS ]

Explore These Compounds

Body Composition

AOD-9604

GH Fragment 176-191, Targeted Lipolysis Without Hormonal Side Effects

Read Profile

AOD-9604

GH Fragment 176-191, Targeted Lipolysis Without Hormonal Side Effects

Research Focus Areas
  • Targeted Lipolysis
  • No Hormonal Side Effects
  • Lipogenesis Prevention
  • FDA GRAS Safety Status
Dosages in Published Literature
Protocol300mcg administered subcutaneously once daily
RouteSubcutaneous injection
Duration12-20 weeks per cycle
Pen
Body Composition

Tesamorelin

GHRH Analogue, Targeted Visceral Fat Reduction via Pulsatile GH Release

Read Profile

Tesamorelin

GHRH Analogue, Targeted Visceral Fat Reduction via Pulsatile GH Release

Research Focus Areas
  • Clinically Proven Visceral Fat Reduction
  • Improved Lipid Profile
  • Cognitive Function Support
  • Physiological GH Optimization
Dosages in Published Literature
Protocol1-2mg administered subcutaneously once daily
RouteSubcutaneous injection
Duration8-12 weeks per cycle
Pen
Longevity

MOTS-c

Mitochondrial-Derived Peptide, AMPK Activation for Metabolic Optimization

Read Profile

MOTS-c

Mitochondrial-Derived Peptide, AMPK Activation for Metabolic Optimization

Research Focus Areas
  • Metabolic Optimization
  • Exercise Capacity Enhancement
  • Longevity-Associated Signaling
  • Mitochondrial Function Support
Dosages in Published Literature
Protocol5-10mg administered subcutaneously 3 times weekly
RouteSubcutaneous injection
Duration4-8 weeks per cycle
[ PROTOCOL ]

Example specialist-guided Metabolic Protocol

This is an example protocol for educational purposes. A specialist would customize based on metabolic panel, body composition analysis, insulin sensitivity, and individual health profile.

1

Phase 1: Metabolic Activation

Weeks 1-8

Compounds: AOD-9604 300mcg/day fasted AM + MOTS-c 5mg 3x/week

Establishes lipolysis and AMPK activation with metabolic monitoring

2

Phase 2: Optimization

Weeks 9-16

Compounds: AOD-9604 300mcg/day + reassessment of metabolic markers

Continued fat metabolism support with diet and exercise integration

3

Phase 3: Maintenance

Weeks 17-20

Compounds: Taper based on body composition progress

Transition to sustainable lifestyle-maintained body composition

Frequently Asked Questions

Tesamorelin has the strongest evidence for visceral fat reduction, with FDA-approved Phase III clinical trial data showing 15-18% trunk fat reduction measured by CT imaging. AOD-9604 also shows preferential effects on visceral and abdominal fat depots. MOTS-c addresses the underlying metabolic dysfunction that promotes visceral fat accumulation. A specialist would recommend based on metabolic profile and whether you need isolated fat metabolism or broader GH axis support.

All metabolic peptides are research-quality compounds requiring qualified medical supervision. Baseline blood work (fasting glucose, insulin, HbA1c, lipid panel, thyroid, hormonal markers) is essential before initiating any protocol. Growth-hormone-related compounds and AMPK activators interact with metabolic systems that require careful monitoring for safe, effective outcomes.

No. Metabolic peptides enhance the body's fat metabolism mechanisms but are most effective when integrated with proper nutrition and regular exercise. They are not substitutes for lifestyle modification. In fact, MOTS-c's AMPK activation may be synergistic with exercise, and AOD-9604's lipolysis enhancement is optimized with fasted morning administration combined with physical activity.

Scale weight is often misleading because peptide protocols may maintain or increase lean tissue while reducing fat. Medical-grade body composition analysis (DEXA scan) provides accurate tracking of fat mass, lean mass, and regional fat distribution. A specialist may also monitor waist circumference, metabolic blood markers (triglycerides, fasting glucose, insulin), and visceral fat estimates to comprehensively assess progress.

Metabolic peptides interact significantly with glucose metabolism. MOTS-c and metformin share the AMPK activation pathway, and Tesamorelin's GH stimulation can temporarily affect insulin sensitivity. Individuals with diabetes or pre-diabetes require careful specialist monitoring with frequent glucose testing to prevent hypoglycemic events and adjust diabetes medications accordingly. AOD-9604 has the most favorable glucose profile, as it does not affect blood sugar.

Want to explore peptide options for Fat Loss & Metabolism?

A specialist can review the evidence and help determine the best approach for your needs.

Speak with a Specialist Free initial consultation. No obligation.
EDITORIAL REVIEW

Reviewed by the Peptide Science Thailand Editorial Team.

Last reviewed: March 1, 2026

Not Medical Advice

The information provided on this website, including compound profiles, mechanism of action explanations, research summaries, dosage information, and educational content, is for informational and educational purposes only. This information does not constitute medical advice, diagnosis, or treatment recommendations. No content on this website should be interpreted as a substitute for professional medical advice, diagnosis, or treatment.

Medical Supervision Essential

All peptide compounds discussed on this website should only be used under the supervision of a qualified specialist. A healthcare provider should evaluate individual health status, medical history, current medications, and specific health objectives before any peptide use. Self-administration of research peptides without medical supervision is strongly discouraged and may pose significant health risks.

Individual Variation

Individual responses to peptide compounds vary significantly based on genetics, age, body composition, existing health conditions, concurrent medications, and other biological factors. Dosage information provided on this website represents general research ranges and should not be used for self-dosing. A qualified specialist should determine the appropriate compound, dosage, administration route, cycle duration, and monitoring protocol based on individual health assessment.

Liability Limitation

Peptide Science Thailand assumes no liability for the misuse of information provided on this website. The content is provided for educational purposes only. Users are responsible for ensuring they work with qualified healthcare providers before using any peptide compounds discussed herein. Peptide Science Thailand is not responsible for adverse effects resulting from use without proper medical oversight.

Regulatory Status

Many peptides discussed here have not been evaluated or approved by the FDA for therapeutic use unless specifically noted (e.g., Tesamorelin, PT-141). The regulatory status of peptide compounds varies by jurisdiction. Some compounds discussed on this website are approved medications in other countries (e.g., Semax and Selank in Russia). This content is for informational and educational purposes only. Users are responsible for understanding and complying with all applicable laws and regulations in their jurisdiction.